Concepedia

Hayato Mizuta

HM

Statistics

Publications

6

Citations

263

H-Index

6

Active since

2020

Affiliations

Institut Gustave Roussy(Current)

Keio University

Université Paris-Saclay

Inserm

RIKEN Center for Sustainable Resource Science

Hayato Mizuta is an author at Institut Gustave Roussy specializing in tyrosine kinase inhibitors, oncology, and medicine.

ORCID

Publications per year

2020–2024

6

Publications

6

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Hayato Mizuta, Koutaroh Okada, Mitsugu Araki et al. · Nature Communications · 2021 · 100 citations · Full text

, , +14

Resistance to Selective FGFR Inhibitors in <i>FGFR-</i> Driven Urothelial Cancer

Francesco Facchinetti, Antoine Hollebecque, Floriane Brayé et al. · Cancer Discovery · 2023 · 76 citations · Full text

, , +14

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz et al. · Cancer Discovery · 2024 · 45 citations · Full text

, , +13

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes

Koh Furugaki, Takaaki Fujimura, Hayato Mizuta et al. · npj Precision Oncology · 2023 · 17 citations · Full text

, , +17

The fibrinogen C-terminal domain is seldom C-mannosylated but its C-mannosylation is important for the secretion of microfibril-associated glycoprotein 4

Yoshiyuki Osada, Takehiro Suzuki, Hayato Mizuta et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 2020 · 15 citations

, , +11

1–5 of 6